img
REACH Insurance Coverage & Assistance

Introducing the NexConnect Patient Support Program

Learn more Enroll online


- + Text Zoom

The REACH® Program — Essential Support Is Within REACH®

Get more information about insurance coverage for Nexavar

Helps patients who have been prescribed Nexavar access medication by identifying specialty pharmacies and addressing insurance and reimbursement concerns.

Nexavar is distributed through specialty pharmacy providers, not through retail pharmacies.

Contact a REACH Program Counselor by calling 1.866.NEXAVAR or 1.87.REACH.4.IT (1.877.322.4448) Monday through Friday from 9 AM to 8 PM EST.

A REACH Program Counselor can:

  • Answer clinical questions about Nexavar
  • Answer your patient's questions about insurance coverage, including questions about the new Medicare Part D drug benefit
  • Assist your patient with contacting their insurance company about covering Nexavar
  • Identify and help your patient apply for alternate sources of coverage and payment for Nexavar, if needed
  • Review your patient's eligibility, if necessary, for Nexavar patient assistance if they do not have insurance

After verifying your patient's insurance coverage, the REACH Program Counselor will send their prescription to a specialty pharmacy provider (SPP). The SPP will fill their prescription and arrange for delivery of Nexavar to them. Before each refill is due, they will receive a call to arrange the next delivery.

  • Nexavar will not be filled through retail pharmacies.
  • Nexavar can be obtained through the REACH Program.

Next: Program Overview
 
Term
Explanation for term.

Indications and Usage


Nexavar is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and for the treatment of patients with advanced renal cell carcinoma (RCC)

Important Safety Considerations


Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required.

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar.

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction.

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs 25%), fatigue (46% vs 45%), abdominal pain (31% vs 26%), weight loss (30% vs 10%), anorexia (29% vs 18%), nausea (24% vs 20%), and hand-foot skin reaction (21% vs 3%). Grade 3/4 adverse reactions were 45% vs 32%.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar. Caution is recommended when administering Nexavar with compounds that are metabolized/eliminated predominantly by the UGT1A9 pathway, UGT1A1 pathway (eg, irinotecan), doxorubicin, docetaxel, fluorouracil, and substrates of CYP2B6 and CYP2C8, and CYP3A4 inducers. Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR, or clinical bleeding episodes.

Women of childbearing potential are advised to avoid becoming pregnant and against breastfeeding.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.